engleski

Interferon beta 1a-induced bronchiolitis obliterans organizing pneumonia: A case report

Recombinant interferons (alpha and beta) are used as immunomodulators in treating viral infections (hepatitis B and C), malignant and lymphoproliferative diseases and multiple sclerosis (interferon beta). Nonspecific side effects of interferon are found in up to 1/3 of patients. Drug induced lung diseases are rare. We present a 50-year old man who was diagnosed with multiple sclerosis in 2009, and started treatment with interferon beta 1a in 2011. He was receiving it subcutaneously every 14 days. After one year nonspecific symptoms ocured, febrility up to 39°C and dry cough, followed by dyspnea. Chest X-ray was normal, but HRCT of thorax showed consolidates in both lower lung lobes, tree in bud lesions, bilateral pleural effusions and air trapping during expiration. PFT's showed restrictive ventilation disorders (FVC 73%, FEV1 62.8%, FEV1/VC 100.8%) and decreased DLco (69%). The diagnosis of bronchiolitis obliterans organizing pneumonia was made by PHD analysis of tranbronchial lung biopsy. Discontinuation of interferon beta 1a was recommended, which was followed by the regression of lung infiltrates, therefore no corticosteroid therapy was necessary. Follow-up HRCT of thorax and pulmonary functional tests (FVC 92.5%, FEV1 92.5%, FEV1/VC 108%, DLco 92.5%) after one year were normal. According to the literature, the case we presented would be the second case of BOOP associated with the use of interferon beta 1a

Drug-induced lung disease; interstitial lung disease

nije evidentirano